Real-World Utilization Patterns of Intravenous Immunoglobulin in Adults With Generalized Myasthenia Gravis in the United States

Objective To evaluate real-world utilization patterns of intravenous immunoglobulin (IVIg) among patients with generalized myasthenia gravis (gMG) over 3 years post-IVIg initiation. Background gMG is a rare autoimmune neuromuscular disorder no known cure. Although IVIg the most commonly used add-on therapy after standard care treatments in gMG, it currently unclear whether more as “one-off” treatment to manage exacerbations, or maintenance aimed at reducing replacing steroid use. Design/Methods Patients who initiated were identified from US claims database (Symphony Health, an ICON plc Company, Integrated Dataverse [IDV]®, January 1, 2014-December 31, 2019). The frequency subsequent and associated cost during first 12 months initiation analyzed. Usage concomitant year preceding compared. Results Among 1225 treatment, 706 (57.6%) received 1 5 courses (intermittent users), 519 (42.4%) = 6 (chronic users) within year. Mean annual medical per patient was nearly 2.5-fold higher for chronic vs intermittent users ($161,478 $64,888, p < 0.001). other immunotherapy did not decrease follow-up period, even continued consecutive post-initiation. Conclusions Nearly half multiple once initiating indicating usage than expected. For all initiators, despite